3 transcripts
IMCR
Earnings call transcript
NASDAQ
2024 Q2
8 Aug 24
, these 2 expansions may allow up to 6,000 patients to benefit from the survival benefit of KIMMTRAK.
Moving to the second strategic pillar, our aim
IMCR
Earnings call transcript
NASDAQ
2023 Q4
28 Feb 24
to potentially expand the benefit of KIMMTRAK to additional indications with our clinical program, which I will take you through in the next slide.We believe
IMCR
Earnings call transcript
NASDAQ
2023 Q2
10 Aug 23
pipeline.
In the first half of the year, KIMMTRAK revenue was $111 million. That growth reflects a robust commercial execution and the recognized benefit
- Prev
- 1
- Next